Kliniken & Institute ... Interdisziplinäre... Liver Cancer Center... Für Patienten Klinische Studien

Klinische Studien

rekrutierend

Name Sponsor Studiengegenstand Phase Entität Stadium
PROMETHEUS IIT Phase I study evaluating the treatment of patients with advanced hepatocellular carcinoma (HCC) with Carbon Ion Radiotherapy 1 HCC Lokal fortgeschritten
CRUSH II   Clamp-crushing vs. Stapler hepatectomy   HCC Rezesierbar HCC
CFGF401X2101 Novartis Phase I/II Studie mit FGF401 in Patienten mit hepatozellulärem Karzinom oder soliden Tumoren, die durch positive FGFR4- und KLB-Expression charakterisiert sind 1/2 HCC/CC palliative Zweitlinie
ACTICCA-1 AIO/UKE Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) 3 CC adjuvant
MK 3475 224 Merck/MSD Pembrolizumab 2 HCC Palliative therapy 2nd -Line
MK 3475-240 Merck/MSD Pembrolizumab vs. BSC 3 HCC Palliative therapy 2nd -Line

 

Rekrutierung abgeschlossen

Name Sponsor Studiengegenstand Phase Entität Stadium
MIRACLE I CeloNova BioSciences, Inc. Microparticle Enhanced Cytotoxic Transarterial Embolization Therapy in Hepatocellular Carcinoma (MIRACLE I) 3 HCC Palliative Therapie, lokal fortgeschritten
CA209-040 BMS A Phase I Dose Escalation Study of Anti-Programmed-Death-1 (PD-1) Antibody (BMS-936558) in Advanced Hepatocellular Carcinoma 1/2 HCC Palliative Therapie, Erstlinie
CIDH305X2101 Novartis IDH305 bei Patienten mit rezidivierten Gliomen, AML oder CC mit IDH1-Mutation: eine Studie der Phase I. 1 CC palliative Zweitlinie
Oncosorb BioPheresis GmbH Clinical Study of OncoSorb® in Patients With Advanced Cancer Entities (BP-005) 1 HCC Palliative Therapie, Last-Linie (Solide Tumore)
AMG 386 amgen A Study of the Effectiveness and Safety of AMG 386 and Sorafenib to Treat Advanced or Inoperable Hepatocellular Cancer 2 HCC Palliative Therapie, Erstlinie
HeiLivCa IIT TACE +/- Sorafenib 3 HCC Neoadjuvante Therapie vor LTx
CetuGEX Glycotope GmbH CetuGEX™ in Comparison to Cetuximab for the Treatment of Patients With Head and Neck Cancer (RESGEX) 1 HCC Palliative Therapie Last-Linie (Solide Tumore)
SHELTER   Phase II trial evaluating resminostat in advanced hepatocellular carcinoma (HCC) 2 HCC Palliative Therapie, Zweitlinie (nach Sorafenib)
GATHER Roche A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma 2 HCC Palliative Therapie, Zweitlinie (nach Sorafenib)
BIBF 1120 Boehringer-Ingelheim Phase I/II Comparison of Efficacy and Safety of BIBF 1120 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma 1/2 HCC Palliative Therapie, Erstlinie
INSIGHT Bayer INSIGHT - Post Marketing Surveillance (INSIGHT) 4 HCC Palliative Therapie, Erstlinie
SPACE Bayer A Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC). 3 HCC Lokal fortgeschritten
SOCS MedImmune LLC MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC. (MEDI-573-1028) 2 HCC Palliative Therapie, Erstlinie
TRAVERSE Jenerex A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib (TRAVERSE) 2b HCC Palliative Therapie, Zweitlinie, (nach Sorafenib)
BAY86-9766 Bayer Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC) 2 HCC Palliative Therapie, Kras-mutierte Patienten
PICCA AIO Cis/Gem vs. CIS/Gem + Panitumumab 2 CC Palliative Therapie
ARQ197-A-U303 DAIICHI SANKYO PHARMA Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma Who Have Been Treated With One Prior Therapy (METIV-HCC) 3 HCC Palliative Therapie, Zweitlinie (nach Sorafenib)
E7080-G000-304 Eisai A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma 3 HCC Palliative Therapie, Erstlinie
CBGJ398X2204 Novartis A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma 1/2 CC Palliative Therapie, Zweitlinie, bei genetischer FGFR-Alteration
BAY86-9766 Bayer Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC) 2 HCC Palliative Therapie, Erstlinie, Kras-mutierte Patienten
Resorce Bayer Studie mit Regorafenib für Patienten mit fortgeschrittenem HCC nach Sorafenib 3 HCC Palliative Therapie, Zweitlinie (nach Sorafenib)